OpenAI and Broadcom have entered into a partnership that will result in the first dedicated AI chips in OpenAI’s history. The company aims to reduce its reliance on external chip manufacturers — and the market response has been overwhelmingly positive.
Author: Mikolaj Laszkiewicz
Mikolaj Laszkiewicz
An experienced journalist and editor passionate about new technologies, computers, and scientific discoveries. He strives to bring a unique perspective to every topic. A law graduate.
The European Commission has unveiled a new program, Apply AI, which includes €1 billion in funding to accelerate the adoption of artificial intelligence across strategic sectors of the economy.
Novo Nordisk, the Danish giant known for its groundbreaking obesity drugs, has announced the acquisition of Akero Therapeutics for an astonishing $5.2 billion. The main goal behind the deal is access to one of the most promising drugs for MASH (Metabolic Dysfunction-Associated Steatohepatitis).
American company Vektor Medical has received the prestigious CE mark for its non-invasive cardiac arrhythmia mapping system, vMap. This allows them to plan their expansion into the European Union and use artificial intelligence to diagnose heart arrhythmias.
Scientists have managed to engineer viruses that can infect only specific bacteria. This discovery opens up vast opportunities for medical innovation through new forms of therapy — but it also raises serious concerns about potential misuse, including the development of biological weapons.
Dutch firm Pharming Group has announced that its workforce reduction plan is progressing as scheduled. Up to 20% of non-medical staff could lose their jobs — mainly those based at the company’s headquarters. The goal is to boost operational efficiency and achieve profitability more quickly.
Pharmaceutical giant AstraZeneca is betting on AI. The company has just signed a deal worth up to $555 million with U.S.-based startup Algen Biotechnologies. The partnership aims to advance therapies that combine gene editing with artificial intelligence.
The Genio system, developed by the American company Nyxoah, has been implanted in the first patients in the United States after being officially approved by the U.S. Food and Drug Administration (FDA). This groundbreaking implant aims to help treat obstructive sleep apnea (OSA), offering an alternative to traditional CPAP masks.